Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market projected to be worth USD 11.39 billion by 2030.
According to SPER Market Research, the Digital PCR (dPCR) and Real-time PCR (qPCR) Market estimated to reach USD 11.39 billion by 2030 with a CAGR of 8.8%.
The key fuels for the market escalation are; advanced PCR technologies, growing investments, increasing genetic as well as targeted infectious disease, raising the exploit of biomarkers profiling in the disease diagnosis, and the booming Human Genome project.
Impact of COVID-19 on the Digital PCR (dPCR) and Real-time PCR (qPCR) Market
The COVID-19 outbreak has mainly impacted to the healthcare industry; diagnostic industry is one of them. There is a positive impact in the PCR industries. Digital PCR (dPCR) and Real-time PCR (qPCR) has the importance in the diagnostic and drug discovery. The focus of the companies is to produce digital PCR kits for the diagnosis of the infection.
Scope of the report:
Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030
Segments covered By Product & Service, By Application, By End-User, By Region
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered Abbott Laboratories, Agilent Technologies, Analytik Jena AG, Becton, Dikinson and Compan, bioMérieux SA, Bioneer, Bio-Rad Laboratories Inc.Dan, aher Corporation, ELITech Group, Enzo Life Sciences, Inc., Eppendorf, F. Hoffmann-La Roche, Ltd., Fluidigm Corporation, Merck KGaA, Meridian Bioscience, Promega Corporation, QIAGEN N.V., Quidel Corporation, Thermo Fisher Scientific, Takara Bio
Driver: Growing Occurrence of Target Infectious Diseases and Genetic Disorders
Rising incidence of target infectious diseases and genetic disorders, technological advancements in PCR technologies, increasing investments, funds, and grants, increasing use of biomarker profiling for disease diagnostics, successful completion of the Human Genome Project; are the key drives of the escalation of the market.
Restraint: High Device Costs Coupled with dPCR
Technical limitations of qPCR and dPCR techniques, costly device coupled with dPCR; can resist the escalation of the market.
Opportunity: Rising Market Penetration in Emerging Countries
Growing market penetration in emerging countries, shift from plant-derived to genome-based drug discovery; offers enormous opportunities to the players in the market.
Challenges:
Adoption and implementation of MIQE guidelines, is the challenge to the market expansion.
Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Product & Service:
Based on the Product and Service, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR Products & Services (qPCR Reagents and Consumables, qPCR Instruments, qPCR Software and Services), dPCR Products & Services (dPCR Instruments, dPCR Reagents and Consumables, dPCR Software and Services).
Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Application:
Based on the Application, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR Applications (Clinical Applications, Forensic Applications, Research Applications), dPCR Applications (Clinical Applications, Research Applications, Forensic Applications).
Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By End-User:
Based on the End-User, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR End User (Clinical Research Organizations, Forensic Laboratories, Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes), qPCR End User (Clinical Research Organizations, Forensic Laboratories, Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes).
Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Region:
North America, dominates the principal share of this market; and this is because of accessibility to research & development funding, growing acceptance of innovative and novel genomic analysis, escalating use of PCR techniques in the clinical diagnostics, forensics, and commercialization of qPCR/dPCR products.
'
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Digital PCR (dPCR) and Real-time PCR (qPCR) Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Product & Service, 2019-2030 (USD Million)
6.1. qPCR Products & Services
6.1.1. qPCR Reagents and Consumables
6.1.2. qPCR Instruments
6.1.3. qPCR Software and Services
6.2. dPCR Products & Services
6.2.1. dPCR Instruments
6.2.2. dPCR Reagents and Consumables
6.2.3. dPCR Software and Services
7. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Application, 2019-2030 (USD Million)
7.1. qPCR Applications
7.1.1. Clinical Applications
7.1.2. Forensic Applications
7.1.3. Research Applications
7.2. dPCR Applications
7.2.1. Clinical Applications
7.2.2. Research Applications
7.2.3. Forensic Applications
8. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By End-User, 2019-2030 (USD Million)
8.1. dPCR End User
8.1.1. Clinical Research Organizations
8.1.2. Forensic Laboratories
8.1.3. Hospitals and Diagnostic Centers
8.1.4. Pharmaceutical and Biotechnology Companies
8.1.5. Research Laboratories and Academic Institutes
8.2. qPCR End User
8.2.1. Clinical Research Organizations
8.2.2. Forensic Laboratories
8.2.3. Hospitals and Diagnostic Centers
8.2.4. Pharmaceutical and Biotechnology Companies
8.2.5. Research Laboratories and Academic Institutes
9. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. Company Profiles
10.1. Abbott Laboratories
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Agilent Technologies
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Analytik Jena AG
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Becton Dikinson and Company
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. bioMérieux SA
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Bioneer
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Bio-Rad Laboratories Inc.
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Danaher Corporation
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. ELITech Group
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Enzo Life Sciences, Inc.
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. Eppendorf
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. F. Hoffmann-La Roche, Ltd.
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. Fluidigm Corporation
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. Merck KGaA
10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. Meridian Bioscience
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. Promega Corporation
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments
10.17. QIAGEN N.V.
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments
10.18. Quidel Corporation
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments
10.19. Takara Bio
10.19.1. Company details
10.19.2. Financial outlook
10.19.3. Product summary
10.19.4. Recent developments
10.20. Thermo Fisher Scientific
10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments
10. Company Profiles
10.1. Abbott Laboratories
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Agilent Technologies
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Analytik Jena AG
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Becton Dikinson and Company
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. bioMérieux SA
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Bioneer
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Bio-Rad Laboratories Inc.
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Danaher Corporation
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. ELITech Group
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Enzo Life Sciences, Inc.
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. Eppendorf
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. F. Hoffmann-La Roche, Ltd.
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. Fluidigm Corporation
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. Merck KGaA
10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. Meridian Bioscience
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. Promega Corporation
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments
10.17. QIAGEN N.V.
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments
10.18. Quidel Corporation
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments
10.19. Takara Bio
10.19.1. Company details
10.19.2. Financial outlook
10.19.3. Product summary
10.19.4. Recent developments
10.20. Thermo Fisher Scientific
10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments
